Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(60.0%)
Early Phase 1
1(20.0%)
Phase 1
1(20.0%)
5Total
N/A(3)
Early Phase 1(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04447573Not ApplicableUnknown

Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Role: collaborator

NCT04447547Not ApplicableUnknown

Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Role: collaborator

NCT04546893Not ApplicableUnknown

Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia

Role: collaborator

NCT04129099Early Phase 1Unknown

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

Role: collaborator

NCT03312205Phase 1Unknown

CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Role: collaborator

All 5 trials loaded